FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability

• Published in: Journal of headache and pain 2023-03, Vol.24 (1), p.28-28, Article 28
• Main Authors: He, Jiahui, Zhou, Mengting, Zhao, Fanglin, Cheng, Hongrong, Huang, Hao, Xu, Xiaopei, Han, Jian, Hong, Wenwu, Wang, Faming, Xiao, Yujin, Xia, Jinjin, Liu, Kaiming
• Format: Article
• Language: English
• Subjects: Disability; Disability Evaluation; Enzyme-linked immunosorbent assay; FGF-21; Fibroblast Growth Factors; GDF-15; Headache; Headaches; Homeostasis; Humans; Internal Medicine; Medicine; Medicine & Public Health; Metabolic disorders; Metabolism; Migraine; Migraine Disorders - complications; Migraine-related disability; Mitochondria; Mitochondrial Diseases - diagnosis; Molecular interactions in migraine; Neurology; Pain Medicine; Serum levels
• ISSN: 1129-2377; 1129-2369; 1129-2377
• DOI: 10.1186/s10194-023-01563-8

Background Migraine is a prevalent disorder with significant socioeconomic impact. The impairment of metabolic homeostasis in migraine warrants further investigation. Changes in serum levels of Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15) are characteristic of some metabolic and mitochondrial diseases. This study aimed to assess whether the presence of migraine affects serum levels of FGF-21 and GDF-15, and taking metabolic disorders into account as potential confounding factors. Methods We collected serum samples from 221 migraine patients (153 episodic migraineurs and 68 chronic migraineurs) and 124 healthy controls. The serum concentrations of FGF-21 and GDF-15 were measured using an enzyme-linked immunosorbent assay (ELISA) based approach. Clinical variables, including monthly headache days, peak headache pain intensity, the 6-item Headache Impact Test (HIT-6), and the Migraine Disability Assessment (MIDAS), were also addressed. The associations between the clinical variables of migraine patients and serum levels of FGF-21 and GDF-15 were studied. Results In the multiple regression that corrected for age, we found that the serum levels of FGF-21 and GDF-15 were significantly higher in migraine sufferers than in healthy controls. A significant elevation in serum concentration of FGF-21, but not GDF-15, was observed in patients with chronic migraine (CM) compared to those with episodic migraine (EM). Regarding migraine-related disability, higher scores on the HIT-6 and MIDAS were associated with higher levels of FGF-21 and GDF-15. For the receiver operating characteristic (ROC) analysis, the diagnosis of migraine using GDF-15 showed that the area under the ROC curve (AUC) was 0.801 and the AUC of chronic migraine was 0.880. Conclusion Serum GDF-15 and FGF-21 levels are increased in patients with migraine and associated with the severity of migraine-related disability.